Welichem announces closing of non-brokered private placement

    BURNABY, BC, June 7 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V:
WBI), is pleased to announce that it has closed its non-brokered private
placement announced on March 28, 2007.
    The Company has raised gross proceeds of CDN $1,000,000 through the
issuance of 6,666,667 common shares. All securities issued under the private
placement will have a hold period expiring on October 9, 2007. Finder's fees
of $66,842.27 are payable in connection with the private placement.
    The proceeds from the financing will be used by the Company to fund
research, development and working capital.

    About Welichem Biotech Inc.

    Welichem Biotech Inc. is a publicly-traded biotechnology company
developing therapeutic drugs in the fields of autoimmune diseases and cancer.


    York Yingping Guo
    President and Chief Executive Officer

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of the content of this news

    %SEDAR: 00021386E

For further information:

For further information: Andrew Baren, Investor Relations, Tel.: (604)
432-1703 ext. 224, Email: andrewbaren@welichem.com

Organization Profile

Welichem Biotech Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890